Nuvation Bio (NYSE: NUVB) net income
Nuvation Bio reported a net loss of $204.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $567.9m. Earnings per share were −$0.60.
Nuvation Bio's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$204.6m | — | −325.3% | −$0.60 |
| 2024 | −$567.9m | — | −7,213.8% | −$2.11 |
| 2023 | −$75.8m | — | — | −$0.35 |
| 2022 | −$104.2m | — | — | −$0.48 |
| 2021 | −$86.8m | — | — | −$0.44 |
| 2020 | −$41.7m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Nuvation Bio net income compared with its sector
By net income for its latest fiscal year, Nuvation Bio ranks 412th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Nuvation Bio, −325.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 410th | Prime Medicine | −$201.1m | −4,342.4% |
| 411th | Wave Life Sciences | −$204.4m | −478.3% |
| 412th | Nuvation Bio | −$204.6m | −325.3% |
| 413th | Tandem Diabetes Care | −$204.7m | −20.2% |
| 414th | Annexon | −$206.7m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Nuvation Bio
- How much did Nuvation Bio earn in fiscal 2025?
- Nuvation Bio reported a net loss of $204.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $567.9m.
- What are the earnings per share of Nuvation Bio?
- They were −$0.60 in fiscal 2025, compared with −$2.11 in fiscal 2024.
- Where does Nuvation Bio rank in its sector by net income?
- It ranks 412th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Nuvation Bio come from?
- From the annual report (Form 10-K) that Nuvation Bio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Nuvation Bio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Nuvation Bio: the Nuvation Bio page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.